Sangamo BioSciences, Inc.
SGMO announced today the presentation of new data from its ongoing
Phase 2 clinical trial (SB-728-902 Cohort 5) to evaluate a single infusion of
Sangamo's novel ZFP Therapeutic^®, SB-728-T, for the treatment of HIV/AIDS.
The data demonstrate functional control of the virus at or below the limit of
detection in CCR5 delta-32 heterozygote HIV-infected subjects treated with
SB-728-T. The abstract was selected as a "late-breaker" presentation at the
53^rd Interscience Conference on Antimicrobial Agents and Chemotherapy
(ICAAC). On Wednesday, September 11, data were also presented demonstrating
depletion of the HIV viral reservoir in SB-728-T treated subjects in cohorts
1-3 of the SB-728-902 study.
Data from the late-breaking presentation demonstrate that viral load (VL)
became undetectable during a treatment interruption (TI) from antiretroviral
therapy (ART) in three of seven evaluable CCR5 delta-32 heterozygote
HIV-infected subjects, including two of six subjects that had completed TI in
the ongoing SB-728-902 Cohort 5 study and an additional subject from an
earlier Phase 1 clinical trial of SB-728-T. In one SB-728-902 Cohort 5
subject, VL has remained undetectable (at or below the limits of
quantification (LOQ) of the current ultra-sensitive assays for HIV) for seven
weeks (to last measurement taken) and the TI is ongoing. Reduction in VL from
peak during TI showed a statistically significant correlation (p=0.015) with
estimated numbers of engrafted ZFN modified cells (SB-728-T) in which both
copies of the CCR5 gene had been disrupted (biallelic modification), in line
with previously presented data from this program.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in